Aeromics has announced a collaboration and exclusive license agreement with China’s Simcere Pharmaceutical Group for Aeromics’ AER-271, a clinical-stage anti-edema therapy, being developed for the treatment of stroke and other indications.
According to the agreement, Simcere will be responsible for the clinical development and commercialization of AER-271 in Greater China (mainland China, Hong Kong, Macau and Taiwan).
“We are delighted to be working with Simcere to develop AER-271 in China. Simcere’s leading position in the Greater China stroke market, their strengths in manufacturing and the collaborative nature of their team made for an ideal partner for Aeromics,” said Thomas Zindrick, Aeromics’ Executive Vice Chairman. more